NCT06066606

U-LABA/ICS Effects on Exercise Performance, Vilanterol

Physiological Response to U-LABA/ICS With Emphasis on Exercise Performance, Vilanterol

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Morten Hostrup, PhD · Academic / Other
• Sex: All
• Age: 18 Years – 39 Years
• Healthy volunteers: Accepted

Summary

The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist vilanterol + fluticasone furoate

Conditions

• Exercise Performance

Interventions

Type	Name	Description
DRUG	Vilanterol and Fluticasone Furoate (low dose)	Participants are administered 25 µg of vilanterol + fluticasone furoate
DRUG	Vilanterol and Fluticasone Furoate (high dose)	Participants are administered 100 µg of vilanterol + fluticasone furoate
DRUG	Placebo	Participants are administered placebo

Timeline

• Start date: 2023-10-03
• Primary completion: 2026-07-15
• Completion: 2026-12-01
• First posted: 2023-10-04
• Last updated: 2025-04-10

Locations

1 site across 1 country: Denmark